Product Program year 2025 Source: CMS Open Payments

Actemra

Biological Immunology

NDC 50242-137-01

Open in the dashboard

General payments

$22,039,912

29,240 payments

Research payments

$227,457,539

13,309 payments

Through program year 2025, $22,039,912 in general payments and $227,457,539 in research payments were reported against Actemra (Immunology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

14 rows
Year Kind Amount Payments
2025 General $82,002 2,129
2025 Research $36,280,489 2,276
2024 General $87,166 2,812
2024 Research $33,464,229 4,209
2023 General $76,171 2,706
2023 Research $41,291,153 1,547
2022 General $178,834 2,604
2022 Research $30,143,491 1,461
2021 General $749,107 4,168
2021 Research $35,906,296 2,026
2020 General $3,263,873 2,727
2020 Research $38,429,902 1,296
2019 General $17,602,758 12,094
2019 Research $11,941,979 494

Breakdown

Who paid General payments · program years 2019–2025
  1. Genentech, Inc. $20,691,994 475 payments
  2. Genentech USA, Inc. $1,100,370 28,592 payments
  3. F. Hoffmann-La Roche AG $214,351 153 payments
  4. Hoffmann-La Roche Limited $15,713 10 payments
  5. Roche Products Limited $13,844 8 payments
  6. Chugai Pharmaceutical Co., Ltd. $3,640 2 payments
Top recipients General payments · program year 2025
  1. John Cush Rheumatology · Dallas, TX $28,000 34% · 1 payment
  2. Cesar Briceno Ophthalmology · Philadelphia, PA $3,570 4% · 2 payments
  3. Atif Collins Ophthalmic Plastic and Reconstructive Surgery · Fresno, CA $2,875 4% · 2 payments
  4. John Leonard Hematology & Oncology · New York, NY $2,640 3% · 1 payment
  5. Matthew Matasar Medical Oncology · New York, NY $1,980 2% · 2 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Rheumatology Internal Medicine $52,202 64% · 715 practitioners
  2. Physician Assistant $4,245 5% · 153 practitioners
  3. Ophthalmic Plastic and Reconstructive Surgery Ophthalmology $4,025 5% · 2 practitioners
  4. Ophthalmology $3,584 4% · 2 practitioners
  5. Nurse Practitioner, Family Nurse Practitioner $3,448 4% · 124 practitioners

The top 5 of 55 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. Texas $30,123 37% · 81 recipients
  2. New York $8,473 10% · 80 recipients
  3. California $7,527 9% · 114 recipients
  4. Pennsylvania $6,680 8% · 70 recipients
  5. Florida $3,528 4% · 134 recipients

The top 5 of 45 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

69,536

Prescriptions dispensed, refills included

Drug cost

$271,216,463

Paid at the pharmacy, in all

Medicare Part D drugs matched to Actemra, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Actemra Actpen Tocilizumab Similar name 1,882 44,475 $180,678,930
Actemra Tocilizumab Same name 1,191 25,061 $90,537,534

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 187 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Elvin Garcia Rheumatology TX 368 $957,934 None on record
Naiara Alvarez Rheumatology TX 288 $771,514 None on record
Eric Panahi Internal Medicine CA 220 $540,498 None on record
Gerald Ho Rheumatology CA 217 $442,300 None on record
Srikanth Naramala Rheumatology CA 207 $787,490 $24

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 187 with Patron

Given in the clinic

Part B · billing code
Medicare Part B billing codes matched to Actemra
Billing code Providers Services Paid by Medicare
Injection, tocilizumab, 1 mg J3262 722 35,790,556 $166,745,517

Drugs given by a clinician are billed to Medicare Part B, not Part D. The product is tied to a billing code through the NDC on CMS's crosswalk, which was published for a later quarter than the payments, so a code that changed in between can be missed. Providers with fewer than 11 patients for the code are not published. Medicare's payment here is what it paid for the services, to the billing practice.

29,240 general · 13,309 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record